Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.9% year on year to $17.76 billion. On the other hand, the company ...

Pfizer beats Q4 estimates with 24.9% revenue growth, reaffirming 2025 guidance and targeting $4.5 billion in cost savings ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Pfizer reported $63.6 billion in revenue for the full year, up 7% compared to 2023. The full-year revenue beat Wall Street ...

US pharma giant Pfizer reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial ...

Pfizer (PFE) is set to announce Q4 earnings, with analysts expecting a $0.46 profit per share and $17.26B revenue.

Pfizer (NYSE: PFE) posted adjusted earnings per share of $0.63 for Q4, exceeding the analyst consensus of $0.48. Revenue came ...

Drug major Pfizer Inc. (PFE), while reporting a profit in its fourth quarter, compared to prior year's loss, on Tuesday reaffirmed ...

Cramer noted that the Dow plunged by 337 points, the S&P 500 fell 0.5%, and the Nasdaq declined by 0.28%. Adding fuel to the ...

Pfizer ( PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...